

# Antimicrobial susceptibility of strains of Enterobacteriaceae isolated from bloodstream infections using current CLSI and EUCAST breakpoints

Giovanna Blandino\*, Silvana Mastrojeni, Rosanna Inturri, Agata Sciacca, Giuseppe Nicoletti

Department of Bio-Medical Sciences, Section of Microbiology, University of Catania, Catania, Italy;

\*Corresponding Author: [blandino@unict.it](mailto:blandino@unict.it), [smastrojeni@hotmail.com](mailto:smastrojeni@hotmail.com), [rosanna.pas@gmail.com](mailto:rosanna.pas@gmail.com), [asciaccia@unict.it](mailto:asciaccia@unict.it), [g.nicoletti@unict.it](mailto:g.nicoletti@unict.it)

Received 17 November 2013; revised 25 December 2013; accepted 8 January 2014

Copyright © 2014 Giovanna Blandino *et al.* This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In accordance of the Creative Commons Attribution License all Copyrights © 2014 are reserved for SCIRP and the owner of the intellectual property Giovanna Blandino *et al.* All Copyright © 2014 are guarded by law and by SCIRP as a guardian.

## ABSTRACT

Understanding local susceptibility patterns is important when selecting antimicrobials for initial empirical antibiotic-therapy of bloodstream infections. Because the determination of susceptibility is dependent on the breakpoints used, the aim of the study was to compare the antimicrobial susceptibility results to different classes of antibiotics of 512 strains of Enterobacteriaceae (200 ES $\beta$ L positive) isolated from bloodstream using CLSI 2013 and current EUCAST 2013 guidelines to evaluate the impact of breakpoint discrepancies. The results of the study showed that statistically significant discrepancies ( $p \leq 0.001$ ) were found for amoxicillin/clavulanic acid, piperacillin alone or with tazobactam, imipenem, meropenem, cefepime (only ES $\beta$ L negative isolates), amikacin and gentamicin using current CLSI or EUCAST interpretive criteria. Further harmonization of CLSI and EUCAST breakpoints is warranted. This study could give useful information to physicians for managing bloodstream infections caused by Enterobacteriaceae.

## KEYWORDS

Antimicrobial-Susceptibility; CLSI Breakpoints; EUCAST Breakpoints; Enterobacteriaceae; Bloodstream-Infections

## 1. INTRODUCTION

Bloodstream infections (BSI) are a leading cause of

morbidity and mortality. In addition there is an emergence of extended spectrum  $\beta$ -lactamase (ES $\beta$ L) producers along with an alarming increase and spread of multi-drug-resistance among BSI pathogens [1-6]. Antimicrobial resistance surveillance of the local epidemiology is indispensable for the initial antibiotic therapy that in bloodstream infections is always empirical [7].

From 2010 the European Committee on Antimicrobial Susceptibility Testing (EUCAST) [8] and the Clinical and Laboratory Standard Institute (CLSI) [9] published lower susceptibility breakpoints for third-generation cephalosporins to differentiate ES $\beta$ L-positive from ES $\beta$ L-negative isolates of Enterobacteriaceae. Moreover, breakpoint values of other classes of antibiotics mainly for Gram-negative species, were also reviewed [8,9]. Changed CLSI guidelines or the use of EUCAST guidelines have led differences in susceptibility rates, mainly for cephalosporins, and conflicting results in literature [10,11].

The aim of the present study was to compare the antimicrobial susceptibility results to different classes of antibiotics of Enterobacteriaceae isolates from bloodstream using 2013 CLSI [12] and 2013 EUCAST [13] guidelines to evaluate the impact of breakpoint discrepancies on the hospital policies and to give useful information to clinicians to elaborate correct guidelines in initial empirical therapy of bloodstream infections.

## 2. EXPERIMENTAL SECTION

### Bacteria and Susceptibility Testing

We analyzed the MIC results of 512 strains of Enterobacteriaceae (232 *E. coli*, 224 *K. pneumoniae*, 40 *Ente-*

*robacter* spp and 16 *Proteus* spp) isolated from blood specimens from January 2009 to March 2013. Cultures were performed at the central Laboratory of Analysis of the Department of Bio-Medical Sciences of the University of Catania using the BD BACTEC™ 9000 System (Becton Dickinson) with fluorescence detection technology and identification and antimicrobial susceptibility of the clinical isolates were determined using BD Phoenix™. For epidemiological purpose the isolates collected were re-identified using API 20 E (Oxoid) for Enterobacteriaceae and confirmatory testing was carried out by broth microdilution using CLSI methodology [12]. Only one isolate was included for each bacteraemic episode. ESβL and carbapenemase production was detected by screening and confirmatory tests suggested by CLSI guidelines [12]. The antibiotics tested for Gram-negative isolates included ampicillin, amoxicillin/clavulanic acid, piperacillin, piperacillin-tazobactam, imipenem, meropenem, aztreonam, cefepime, cefotaxime, ceftazidime, amikacin, gentamicin, ciprofloxacin and levofloxacin. Quality control testing was performed following CLSI guidelines [12]. For this retrospective study the MIC results were interpreted following the interpretive breakpoints published in 2013 by CLSI [12] and by EUCAST [13].

Percentages obtained by CLSI and EUCAST methodologies were compared using the chi-square test.

### 3. RESULTS AND DISCUSSION

#### 3.1. Results

**Table 1** shows the MIC range, MIC90 and antimicrobial susceptibility data of 512 Enterobacteriaceae isolates as classified by CLSI 2013 [12] and EUCAST 2013 [13] interpretative breakpoints.

ESβL-positive isolates were 200/512 (39%).

For amoxicillin/clavulanic acid and ampicillin EUCAST includes, in the resistant category, the MIC values classified as intermediate by CLSI, but different percentage of resistance was only observed for amoxicillin/clavulanic acid (70% and 64% respectively). For piperacillin alone or with tazobactam, CLSI and EUCAST susceptible breakpoints are  $\leq 16$  mg/l and  $\leq 8$  mg/l and resistant breakpoints  $\geq 128$  mg/l and  $\geq 32$  mg/l respectively. Therefore higher intermediate or resistant rates were observed using EUCAST breakpoints. Significant differences were observed between CLSI and EUCAST results for amoxicillin/clavulanic, piperacillin and piperacillin/tazobactam ( $p$  values for comparison  $< 0.0001$ ,  $= 0.001$  and  $< 0.0001$ , respectively). Even if imipenem and meropenem CLSI susceptible breakpoints are more restrictive than those of EUCAST ( $\leq 1$  mg/l and  $\leq 2$  mg/l respectively), similar percentages of susceptibility were observed for both carbapenems; instead discrepancies

were found for intermediate and resistant rates. In our study MHT performed for intermediate or resistant isolates to both carbapenems using different interpretive criteria, confirmed that only the current CLSI and not EUCAST breakpoints were able to detect 8% of the isolates producing carbapenemase (MIC  $\geq 4$  mg/l). Aztreonam susceptibility and resistance breakpoints respectively are  $\leq 4$  mg/l and  $\geq 16$  mg/l for CLSI and  $\leq 1$  mg/l and  $\geq 8$  mg/l for EUCAST. Results show that irrespective of the breakpoints used, 100% of all the ESβL-negative isolates were susceptible (MIC  $\leq 1$  mg/l) and 100% of the ESβL-positive isolates were resistant (MIC  $\geq 32$  mg/l) to this agent. Susceptibility breakpoints according to CLSI are  $\leq 8$  mg/l for cefepime,  $\leq 1$  mg/l for cefotaxime and  $\leq 4$  mg/l for ceftazidime; susceptibility EUCAST breakpoint is  $\leq 1$  mg/l for the three cephalosporins. The remarkable discrepancy between the two sets of recommendations for cefepime determined a shifting of ESβL-negative strains with MIC of 2 - 4 mg/l from susceptible to intermediate category and a significant difference between CLSI and EUCAST results ( $p < 0.0001$ ). Instead, irrespectively of the breakpoints used, 100% of ESβL negative isolates was susceptible to cefotaxime and ceftazidime.

For amikacin and gentamicin, EUCAST breakpoints for susceptible, intermediate and resistant categories are one dilution lower than CLSI breakpoints, therefore using EUCAST criteria percentages of susceptible strains to these aminoglycosides were lower than those obtained using CLSI (90% vs 100% for amikacin, 66% vs 72% for gentamicin). Differences between CLSI and EUCAST results were statistically significant ( $p < 0.0001$ ).

For ciprofloxacin and levofloxacin EUCAST breakpoints for the susceptible, intermediate and resistant categories are one dilution lower than those suggested by CLSI but no significant difference was determined.

Discrepancies in MICs using BD Phoenix and broth microdilution were not observed.

#### 3.2. Discussion

An updated knowledge of the local epidemiology of antimicrobial resistance based on susceptibility testing is necessary when selecting antibiotics for formulary inclusion and for the initial empirical antibiotic-therapy of bloodstream infections [1]. The determination of susceptibility is dependent on the breakpoints used that vary somewhat based on the agency. Because CLSI 2013 [12] and EUCAST 2013 [13] still suggest different breakpoints, discrepancies due to the guidelines adopted by clinicians could lead to an important impact on the selection of the first-line antibiotic to be used in bloodstream infections increasing the use the carbapenems and leading to resistance and loss of therapeutic treatment options [10,11,14].

**Table 1.** Antimicrobial susceptibility of 512 strains of Enterobacteriaceae isolated from bloodstream infections as classified by CLSI 2013 [12] and EUCAST 2013 breakpoint criteria [13].

Enterobacteriaceae (ESβL – ve 312; ESβL + ve 200) (MHT positive 41)	CLSI			EUCAST			* <i>p</i> value	MIC range (mg/l)	MIC90 (mg/l)
	S % (isolates)	I % (isolates)	R % (isolates)	S % (isolates)	I % (isolates)	R % (isolates)			
Ampicillin	9% (46)	-	91% (466)	9% (46)	n.p.	91% (466)	n.s.	4-≥32	≥32
Amoxicillin/ clavulanic acid	30% (153)	6% (31)	64% (328)	30% (154)	n.p.	70% (358)	<0.0001	≤4/2-≥32/16	≥32/16
Piperacillin	36% (184)	2% (10)	62% (318)	30% (153)	6% (31)	64% (328)	=0.001	≤4-≥128	≥128
Piperacillin/ Tazobactam	56% (287)	8% (41)	36% (184)	55% (282)	1% (5)	44% (225)	<0.0001	≤4/2-≥128/4	≥128/4
Imipenem	88% (451)	1% (5)	11% (56)	89% (456)	5% (25)	6% (31)	<0.0001	≤1-≥16	4
Meropenem	91% (466)	1% (5)	8% (41)	92% (471)	6% (31)	2% (10)	<0.0001	≤1-≥16	≤1
Aztreonam	61% (312)	-	39% (200)	61% (312)	-	39% (200)	n.s.	≤1-≥32	≥32
Aztreonam ESβL + ve	-	-	100% (200)	-	-	100% (200)	n.s.	≥32	≥32
Aztreonam ESβL – ve	100% (312)	-	-	100% (312)	-	-	n.s.	≤1	≤1
Cefepime	61% (312)	-	39% (200)	59% (302)	2% (10)	39% (200)	=0.006	≤1-≥32	≥32
Cefepime ESβL + ve	-	-	100% (200)	-	-	100% (200)	n.s.	≥32	≥32
Cefepime ESβL – ve	100% (312)	-	-	96% (300)	4% (12)	-	<0.0001	≤1-4	≤1
Cefotaxime	61% (312)	-	39% (200)	61% (312)	-	39% (200)	n.s.	≤1-≥64	≥64
Cefotaxime ESβL + ve	-	-	100% (200)	-	-	100% (200)	n.s.	16-≥64	≥64
Cefotaxime ESβL – ve	100% (312)	-	-	100% (312)	-	-	n.s.	≤1	≤1
Ceftazidime	61% (312)	-	39% (200)	61% (312)	-	39% (200)	n.s.	≤1-≥32	≥32
Ceftazidime ESβL + ve	-	-	100% (200)	-	-	100% (200)	n.s.	16-≥32	≥32
Ceftazidime ESβL – ve	100% (312)	-	-	100% (312)	-	-	n.s.	≤1	≤1
Amikacin	100% (512)	-	-	90% (461)	10% (51)	-	<0.0001	≤8-16	≤8
Gentamicin	72% (369)	3% (15)	25% (128)	66% (338)	6% (31)	28% (143)	<0.0001	≤2-≥16	≥16
Ciprofloxacin	80% (410)	2% (10)	18% (92)	79% (405)	1% (5)	20% (102)	n.s.	≤0.5-≥4	≥4
Levofloxacin	81% (415)	1% (5)	18% (92)	80% (410)	1% (5)	19% (97)	n.s.	≤1-≥8	≥8

n.p.: no published criteria; n.s.: no significant difference; \* *p*-value for comparing CLSI and EUCAST results: chi-square test.

Discrepancies between CLSI and EUCAST breakpoints for extended-spectrum cephalosporins have a significant impact on whether an invasive ESβL-producing isolate is classified as susceptible to these agents. Schito *et al.* [15] demonstrated that, in general, discrepancies between CLSI 2009 and EUCAST resulted in modest (≤ 4%) differences in the percentages of susceptible isolates of *E. coli*, responsible for UTIs, for all antimicrobial agents tested with the exception of cefuroxime (95% vs 82%), but the study did not screen isolates for ESβL production. Hombach *et al.* [16] have demonstrated that significant differences in the susceptibility rates of important cephalosporins such as cefepime, ceftazidime and cefotaxime applying EUCAST 2013 and CLSI 2013 guidelines were detected for ESβL- and AmpC β-lactamase-producing isolates. Using CLSI 2010 or EUCAST breakpoints, Hawser *et al.* [17] and Kristo *et al.* [18] demonstrated that a proportion of ESβL-positive isolates may be reported as susceptible to expanded-

spectrum cephalosporins, leading to possible infection control and therapeutic implication. Moreover Hawser *et al.* [17] suggested that confirmation testing of ESβL phenotypes to ceftazidime, ceftriaxone, and cefotaxime could be helpful to monitor evolving epidemiology of ESβL-positive isolates. In this retrospective study, on the basis of MIC results of aztreonam and cephalosporins tested for Enterobacteriaceae, using 2013 CLSI [12] or EUCAST breakpoints [13], it was possible to differentiate ESβL-positive (MIC ≥ 4 mg/l) from ESβL-negative isolates (MIC ≤ 1 mg/l) for aztreonam, cefotaxime and ceftazidime. The ESβL-negative strains classified as intermediate to cefepime according to EUCAST and included in the susceptible category by the CLSI, suggest that less restrictive CLSI breakpoints for this cephalosporin could better designate the ESβL-negative isolates. However discrepancies between studies might be attributable to differences in regional prevalence of the ESβL type in *E. coli*, as suggested by Rodriguez-Baño *et al.*

[19].

Using CLSI 2010 and or EUCAST 2011 guidelines, discrepancies with piperacillin-tazobactam were found by Rodriguez-Baño *et al.* [19] in the percentages of susceptibility to piperacillin-tazobactam, particularly among CTX-M1 producers. In our study, using current CLSI or EUCAST guidelines discrepancies were statistically significant for amoxicillin/clavulanic acid, piperacillin alone or with tazobactam.

In our study, significant differences ( $p < 0.0001$ ) were found in the results using CLSI or EUCAST methodologies for imipenem and carbapenem. However eight percent of the strains with Modified Hodge Test (MHT) positive results can be discarded only using CLSI breakpoints.

Adopting current CLSI and EUCAST breakpoints significant discrepancies ( $p < 0.0001$ ) were found for amikacin and, at less extent, for gentamicin. Statistically significant discrepancies in the susceptibility ( $p < 0.01$ ) have been also found for amikacin by Rodriguez-Baño *et al.* [19].

The adoption of more restrictive EUCAST breakpoints, that are one dilution lower than those suggested by the CLSI, could permit a rapid detection of plasmid-mediated resistance to fluoroquinolones, that causes only a modest increase in MICs [15].

On the basis of this study, the adoption by clinical laboratories of current CLSI or EUCAST interpretive criteria, for these antimicrobial agents, could influence the decision to be taken by the physicians managing patients with bloodstream infections caused by Enterobacteriaceae and determine treatment implications. Anyway more clinical data are necessary to support the present CLSI and EUCAST criteria in different infections. Because differences in susceptibility rates are still detected, further harmonization of CLSI and EUCAST breakpoints is warranted.

## ACKNOWLEDGEMENTS

We are grateful to Dr. Filippo Palermo of the University of Catania for statistical support.

## CONFLICT OF INTEREST

The authors declare no conflict of interest.

## REFERENCES

- [1] Tumbarello, M., Sanguinetti, M., Montuori, E., Trecarichi, E.M., Posteraro, B., Fiori, B., Citton, R., D'Inzeo, T., Fadda, G., Cauda, R. and Spanu, T. (2007) Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: Importance of inadequate initial antimicrobial treatment. *Antimicrobial Agents and Chemotherapy*, **51**, 1987-1994. <http://dx.doi.org/10.1128/AAC.01509-06>
- [2] Blandino, G., Nicoletti, G. and Nicolosi, D. (2011) Susceptibility of molecularly characterized hospital-associated methicillin-resistant *Staphylococcus aureus* isolates to dalbavancin. *Journal of Chemotherapy*, **23**, 306-307.
- [3] Chazan, B., Raz R., Teitler, N., Nitzan, O., Edelstein, H. and Colodner, R. (2009) Epidemiology and susceptibility to antimicrobials in community, hospital and long-term care facility bacteremia in northern Israel: A 6 year surveillance. *Israel Medical Association Journal*, **11**, 592-597.
- [4] Kallen, A.J., Hidron, A.I., Patel, J. and Srinivasan, A. (2010) Multidrug resistance among gram-negative pathogens that caused healthcare-associated infections reported to the National Healthcare Safety Network, 2006-2008. *Infection Control and Hospital Epidemiology*, **31**, 528-531. <http://dx.doi.org/10.1086/652152>
- [5] Moehario, L.H., Tjoa, E., Kiranasari, A., Ningsih, I., Rosana, Y. and Karuniawati, A. (2009) Trends in antimicrobial susceptibility of gram-negative bacteria isolated from blood in Jakarta from 2002 to 2008. *Journal of Infection in Developing Countries*, **3**, 843-848.
- [6] Nicolosi, D., Nicolosi, V.M., Cappellani, A., Nicoletti, G. and Blandino, G. (2009) Antibiotic susceptibility profiles of uncommon bacterial species causing severe infections in Italy. *Journal of Chemotherapy*, **21**, 253-260.
- [7] European Centre for Disease Prevention and Control (ECDC) (2012) Antimicrobial resistance surveillance in Europe 2011. Surveillance Report. [www.ecdc.europa.eu](http://www.ecdc.europa.eu)
- [8] The European Committee on Antimicrobial Susceptibility testing (2010) Breakpoint tables for interpretation of MIC<sub>s</sub> and zone diameters. Version 1.1, EUCAST. [http://www.eucast.org/antimicrobial\\_susceptibility\\_testing/previous\\_versions\\_of\\_tables/](http://www.eucast.org/antimicrobial_susceptibility_testing/previous_versions_of_tables/)
- [9] Clinical and Laboratory Standards Institute (2010) Performance standards for antimicrobial susceptibility testing. 20th Informational Supplement Document M100-S20, CLSI, Wayne.
- [10] Hombach, M., Wolfensberg, A., Kuster, S.P. and Böttger, E.C. (2013) Influence of clinical breakpoint changes from CLSI 2009 to EUCAST 2011 antimicrobial susceptibility testing guidelines on multidrug resistance rates of Gram-negative rods. *Journal of Clinical Microbiology*, **51**, 2385-2387. <http://dx.doi.org/10.1128/JCM.00921-13>
- [11] Van der Bij, A.K., Van Dijk, K., Muilwijk, J., Thijsen, S.F., Notermans, D.W., De Greeff, S. and Van de Sande-Bruinsma, N. (2012) ISIS-AR study group. Clinical breakpoint changes and their impact on surveillance of antimicrobial resistance in *Escherichia coli* causing bacteraemia. *Clinical Microbiology and Infection*, **18**, E466-E472. <http://dx.doi.org/10.1111/j.1469-0691.2012.03996.x>
- [12] Clinical and Laboratory Standards Institute (2013) Performance standards for antimicrobial susceptibility testing. 23rd Informational Supplement Document M100-S23, CLSI, Wayne.

- [13] The European Committee on Antimicrobial Susceptibility testing (2013) Breakpoint tables for interpretation of MIC<sub>s</sub> and zone diameters. Version 3.1, EUCAST. [http://www.eucast.org/antimicrobial\\_susceptibility\\_testing/previous\\_versions\\_of\\_tables/](http://www.eucast.org/antimicrobial_susceptibility_testing/previous_versions_of_tables/)
- [14] Nordmann, P., Picazo, J.J., Mutters, R., Korten, V., Quintana, A., Laeuffer, J.M., Seak, J.C., Flamm, R.K. and Morrissey, I. (2011) on behalf of the COMPACT study group. Comparative activity of carbapenem testing: The COMPACT study. *Journal of Antimicrobial Chemotherapy*, **66**, 1070-1078. <http://dx.doi.org/10.1093/jac/dkr056>
- [15] Schito, G.C., Gualco, L., Naber, K.G., Botto, H., Palou, J., Mazzei, T. and Marchese, A. (2010) Do different susceptibility breakpoints affect the selection of antimicrobials for treatment of uncomplicated cystitis? *Journal of Chemotherapy*, **22**, 345-354.
- [16] Hombach, M., Muottet, B. and Bloemberg, G.V. (2013) Consequences of revised CLSI and EUCAST guidelines for antibiotic susceptibility patterns of ESBL-and AmpC  $\beta$ -lactamase-producing clinical Enterobacteriaceae isolates. *Journal of Antimicrobial Chemotherapy*, **68**, 2092-2098.
- [17] Hawser, S.P., Badal, R.E., Bouchillon, S.K., Hoban, D.J. and Hsueh, P.R. (2010) Comparison of CLSI 2009, CLSI 2010 and EUCAST cephalosporin clinical breakpoints in recent clinical isolates of *Escherichia coli*, *Klebsiella pneumoniae* and *Klebsiella oxytoca* from the SMART Global Surveillance Study. *International Journal of Antimicrobial Agents*, **36**, 293-294. <http://dx.doi.org/10.1016/j.ijantimicag.2010.05.012>
- [18] Kristo, I., Pitiriga, V., Poulou, A., Zarkotou, O., Kimouli, M., Pournaras, S. and Tsakris, A. (2013) Susceptibility patterns to extended-spectrum cephalosporins among Enterobacteriaceae harbouring extended-spectrum  $\beta$ -lactamases using the update Clinical and Laboratory Standards Institute interpretative criteria. *International Journal of Antimicrobial Agents*, **41**, 383-387. <http://dx.doi.org/10.1016/j.ijantimicag.2012.12.003>
- [19] Rodriguez-Baño, J., Picó, E., Navarro, M.D., López-Cerero, L., Pascual Á. and the ESBL-REIPI Group (2012) Impact of changes in CLSI and EUCAST breakpoints for susceptibility in bloodstream infections due to extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli*. *Clinical Microbiology and Infection*, **18**, 894-900. <http://dx.doi.org/10.1111/j.1469-0691.2011.03673.x>